The nuclear medicine diagnostics market is projected to grow significantly, expanding from $7.88 billion in 2025 to $8.84 billion in 2026, marking a compound annual growth rate (CAGR) of 12.2%. This growth is driven by the increased use of radioactive tracers and the expansion of nuclear medicine departments. By 2030, the market is expected to reach $13.77 billion, with a CAGR of 11.7%, fueled by investments in precision oncology and improved regulatory support. A key driver for this market expansion is the rising incidence of cancer globally, with projections suggesting an increase from 20 million cancer diagnoses in 2022 to 33 million by 2050. North America currently holds the largest share of the nuclear medicine diagnostics market, while the report also provides insights into other global regions. The report includes various updated elements such as market attractiveness scoring, total addressable market analysis, and a projected future trend assessment.
Thu, 20 Aug 2026 13:49:48 GMT | The National Law Review